Associated Papers
SEAP-GETNE consensus on prognostic and predictive molecular biomarkers in thyroid cancer.
Ruz-Caracuel I et al.
Revista Espanola De Patologia : Publicacion Oficial De La Sociedad Espanola De Anatomia Patologica Y De La Sociedad Espanola De Citologia, 2026
An updated patent review of rearranged during transfection (RET) kinase inhibitors (2022-present).
Armstrong D et al.
Expert Opinion on Therapeutic Patents, 2025
Systemic Therapies for Advanced Medullary Thyroid Carcinoma.
Santillan MR et al.
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer, 2025
Molecular genetics, therapeutics and RET inhibitor resistance for medullary thyroid carcinoma and future perspectives.
Zhang Y et al.
Cell Communication and Signaling : Ccs, 2024
Side Chain Investigation of Imidazopyridazine as a Hinge Binder for Targeting Actionable Mutations of RET Kinase.
Maturi A et al.
Acs Medicinal Chemistry Letters, 2024
Non-Small-Cell Lung Cancers (NSCLCs) Harboring RET Gene Fusion, from Their Discovery to the Advent of New Selective Potent RET Inhibitors: "Shadows and Fogs".
Spitaleri G et al.
Cancers, 2024
Medullary Thyroid Cancer: Molecular Drivers and Immune Cellular Milieu of the Tumour Microenvironment-Implications for Systemic Treatment.
Papachristos AJ et al.
Cancers, 2024
Unraveling the Promise of RET Inhibitors in Precision Cancer Therapy by Targeting RET Mutations.
Wang ZX et al.
Journal of Medicinal Chemistry, 2024
[Precision medicine in endocrinology exemplified by medullary thyroid cancer].
Brandenburg T et al.
Innere Medizin (heidelberg, Germany), 2024
Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations.
Miyazaki I et al.
Nature Cancer, 2023
Targeting RET Solvent-Front Mutants with Alkynyl Nicotinamide-Based Inhibitors.
Khatri U et al.
Molecular Cancer Therapeutics, 2023
Medullary thyroid cancer - An update.
Fugazzola L
Best Practice & Research. Clinical Endocrinology & Metabolism, 2023
Targeting RET alterations in cancer: Recent progress and future directions.
Shabbir A et al.
Critical Reviews in Oncology/hematology, 2023
Pralsetinib: chemical and therapeutic development with FDA authorization for the management of RET fusion-positive non-small-cell lung cancers.
Ali F et al.
Archives of Pharmacal Research, 2022
Non-small-cell lung cancer: how to manage RET-positive disease.
Andrini E et al.
Drugs in Context, 2022
Precision oncology for RET-related tumors.
Verrienti A et al.
Frontiers in Oncology, 2022
How does nintedanib overcome cancer drug-resistant mutation of RET protein-tyrosine kinase: insights from molecular dynamics simulations.
Cao S et al.
Journal of Molecular Modeling, 2021
Targeting Rearranged during Transfection in Cancer: A Perspective on Small-Molecule Inhibitors and Their Clinical Development.
Saha D et al.
Journal of Medicinal Chemistry, 2021
Targeted activity of the small molecule kinase inhibitor Pz-1 towards RET and TRK kinases.
Moccia M et al.
Scientific Reports, 2021
The importance of the RET gene in thyroid cancer and therapeutic implications.
Salvatore D et al.
Nature Reviews. Endocrinology, 2021
Resistance to Avapritinib in PDGFRA-Driven GIST Is Caused by Secondary Mutations in the PDGFRA Kinase Domain.
Grunewald S et al.
Cancer Discovery, 2021
Progresses Toward Precision Medicine in RET-altered Solid Tumors.
Belli C et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2020
Decade in review: a new era for RET-rearranged lung cancers.
Choudhury NJ et al.
Translational Lung Cancer Research, 2020
Molecular Pathology of Primary Non-small Cell Lung Cancer.
Suster DI et al.
Archives of Medical Research, 2020
Advances in Targeting RET-Dependent Cancers.
Subbiah V et al.
Cancer Discovery, 2020
5P Strategies for Management of Multiple Endocrine Neoplasia Type 2: A Paradigm of Precision Medicine.
Li SY et al.
Frontiers in Endocrinology, 2020
RET kinase alterations in targeted cancer therapy.
Liu X et al.
Cancer Drug Resistance (alhambra, Calif.), 2020
Structural basis of resistance of mutant RET protein-tyrosine kinase to its inhibitors nintedanib and vandetanib.
Terzyan SS et al.
The Journal of Biological Chemistry, 2019
Drug resistance profiles of mutations in the RET kinase domain.
Liu X et al.
British Journal of Pharmacology, 2018
Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes.
Drilon A et al.
Nature Reviews. Clinical Oncology, 2018
Clinical and Translational Implications of RET Rearrangements in Non-Small Cell Lung Cancer.
Ferrara R et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, 2018
Resistance to RET-Inhibition in RET-Rearranged NSCLC Is Mediated By Reactivation of RAS/MAPK Signaling.
Nelson-Taylor SK et al.
Molecular Cancer Therapeutics, 2017
The molecular basis for RET tyrosine-kinase inhibitors in thyroid cancer.
De Falco V et al.
Best Practice & Research. Clinical Endocrinology & Metabolism, 2017
Preclinical Modeling of KIF5B-RET Fusion Lung Adenocarcinoma.
Huang Q et al.
Molecular Cancer Therapeutics, 2016